Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY) started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBYGet Rating) in a research report released on Saturday. The firm issued a hold rating on the stock.

NovaBay Pharmaceuticals Stock Performance

NBY stock traded down $0.08 during trading on Friday, reaching $1.50. The stock had a trading volume of 18,810 shares, compared to its average volume of 13,219. The firm has a fifty day moving average price of $2.15 and a 200 day moving average price of $1.19. NovaBay Pharmaceuticals has a 1-year low of $1.24 and a 1-year high of $12.64.

NovaBay Pharmaceuticals Company Profile

(Get Rating)

NovaBay Pharmaceuticals, Inc engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.

Read More

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with's FREE daily email newsletter.